Congress Materials - European Academy of Dermatology and Venereology (EADV 2026)
2026 European Academy of Dermatology and Venerology | Sep 30-Oct 3 | Vienna, Austria
APEX: Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis by Participant Baseline Characteristics
Philip J. Mease, Christopher T. Ritchlin, Laura C. Coates, Alexa P. Kollmeier, Bei Zhou, Yusang Jiang, April W. Armstrong, Karissa Lozenski, Soumya D. Chakravarty, Proton Rahman, Désirée van der Heijde
Consistency of Skin Clearance With the Targeted Oral Peptide Icotrokinra: Results From a Large Pooled Cohort of Phase 3 Study Participants With Moderate-to-Severe Plaque Psoriasis
Linda Stein Gold, April W. Armstrong, Jennifer Soung, Ronald B. Vender, Andrew E. Pink, Joseph Cafone, Bassey Effiom Edem, Ofelia Reyes-Servin, Shu Li, Ya-Wen Yang, Mark G. Lebwohl
Durability of Icotrokinra Effect in Participants With Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis: Pooled Analysis of One-Year Outcomes From the Phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 Trials
April W. Armstrong, Iain B. McInnes, Linda Stein Gold, Mark G. Lebwohl, Ofelia Reyes-Servin, Ya-Wen Yang, Soumya D. Chakravarty, Charles Iaconangelo, Kellen Cresswell, Tasneam Shagroni, Sarah Ofori, Karissa Lozenski, Joseph F. Merola
Durability of Systemic and Skin Pharmacodynamic Responses With Icotrokinra in Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Week 52 Results
Julianty Angsana, Connor Hill, Elizabeth Chen, Sharan Nischal, Deepika Balakrishna, Lynn Tomsho, Marta E. Polak, Christopher Sisk, Arun Kannan, Cynthia DeKlotz, Megan Miller-Kassamali, Joseph Cafone, Ya-Wen Yang, Paul Newbold, Carolyn A. Cuff, Dawn Waterworth, Nina Sabins, James G. Krueger, Andreas Pinter, Robert Bissonnette
Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis and Inadequate Response/Intolerance to One Prior Tumor Necrosis Factor Inhibitor Through 1 Year of the SOLSTICE Study
Alice B. Gottlieb, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Soumya D. Chakravarty, Yanli Wang, Yevgeniy Krol, Stacey Fitch, Alexis Ogdie
Extraintestinal Manifestations in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GALAXI 2 & 3 Studies
Silvio Danese, Tadakazu Hisamatsu, Rian Van Rampelbergh, Wilbert van Duijnhoven, Gustavo Scapini, Shashi Adsul, Alexander Moschen, Miriam Zimmerman, David T. Rubin
Guselkumab Demonstrates Superior Effectiveness Compared With Secukinumab in Overweight/Obese Psoriasis Patients: Results Through 84 Weeks From the Non-Interventional German G-REAL Study
Ralph von Kiedrowski, Daniela Greiner-Krüger, Ansgar Weyergraf, Rolf Ostendorf, Sebastian Zimmer, Sven Quist, Friedemann J.H. Taut, Simmy Jacobsen, Juliane Behrens, Nikolas Spindler, Matthias Hoffmann
Guselkumab Re-Treatment After Withdrawal: Rapid Regain of Disease Control in Super-Responders With Moderate-to-Severe Plaque Psoriasis - Final Week 220 Phase 3b GUIDE Findings
Khusru Asadullah, Andreas Pinter, Kilian Eyerich, Peter Weisenseel, Carle Paul, Friedemann J.H. Taut, Simmy Jacobsen, Jörg Schmitz, Judita Makuc, Nikolas Spindler, Knut Schäkel
Guselkumab Shows Better Long-Term Effectiveness and Drug Survival Compared to Secukinumab Through 84 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis: Results From the German Non-Interventional G-REAL Study
Ralph von Kiedrowski, Sascha Gerdes, Marc H. Segert, Rolf Ostendorf, Durdana Groß, Friedemann J.H. Taut, Lukas Scharfenberger, Simmy Jacobsen, Juliane Behrens, Nikolas Spindler, Matthias Hoffmann
Heterogeneity of the Association Between Body Mass Index and Skin Clearance in Real‑World Ustekinumab‑Treated Patients With Psoriasis in China
Xia Li, Tong Li, Youran Xu, Yongjing Zhang, Hong Qiu, Yeping Ruan, Lihong Chen, Yu Wang, Yuling Shi
Patient-Level Persistence of On-Treatment Remission With Guselkumab: Pooled Results From VOYAGE 1 and VOYAGE 2 Participants With Moderate-to-Severe Plaque Psoriasis
Yayoi Tada, Peter Foley, April W. Armstrong, Joseph F. Merola, Jessie Chang, Steven Fakharzadeh, Emmanouil Rampakakis, Yu-Huei Huang, Luis Puig, Richard G. Langley
Persistence, Effectiveness, Safety, and Patient Reported Impact of Guselkumab and IL-17 Inhibitors in Psoriatic Arthritis: Full Population Results of the PsABIOnd Global Observational Study Over 12 Months
Laure Gossec, Mohamed Sharaf, Frank Behrens, Ennio Lubrano, Mitsumasa Kishimoto, Xenofon Baraliakos, Ruben Queiro Silva, Emmanouil Rampakakis, László Köleséri, Karissa Lozenski, Enrique R. Soriano, Proton Rahman, Stefan Siebert
Pregnancy Outcomes in Maternal Exposure to Guselkumab: Review of Cases Reported to the Company Global Safety Database
Uma Mahadevan, Millie Long, Mette Julsgaard, Connie Lin, Anja Geldhof, Miriam Zimmerman, Mauricio Rosas Ballina, Hewei Li, Javier P. Gisbert, María Chaparro
Real-world treatment patterns, persistence and subsequent treatment following oral therapy discontinuation for psoriasis in Japan
Grace Hui-Min Wu, Jae-eun Lee, Yongjing Zhang, Ko Nakajo, Hiroshi Yamazaki, Jessie Chang, Bryan Wahking, Hong Qiu
Real World, Long Term Persistence of Guselkumab Versus Interleukin-17 Inhibitors in Patients With Psoriasis: Evidence Through Up to 6.5 Years
Luigi Naldi, Ahlem Azzabi, Steven Fakharzadeh, Fowzia Ibrahim, Yerkebulan Kambarov, Yevgeniy Krol, Kimberly Parnell Lafferty, Rongshuang Lin, Yayoi Tada, Miriam Zimmermann, Bruce Strober
Reduction of Skin CD8 TRMs in Icotrokinra-Treated Participants With Moderate-to-Severe Plaque Psoriasis: Phase 3 ICONIC-LEAD Results Through Week 52
Julianty Angsana, Yan Ren, Jocelyn Sendecki, Kristen Kohler, Nathaniel Roscoe, Janina Gooco, Christopher Sisk, Tae Lee, Cynthia DeKlotz, Megan Miller-Kassamali, Joseph Cafone, Paul Newbold, Arun Kannan, Marta E. Polak, Dawn Waterworth, Nina Sabins, Carolyn Cuff, Killian Eyerich, Kerstin Wolk, Robert Sabat, Heena Mehta, Marika Sarfati, Sonja Molin, Robert Bissonnette
SPECTREM: Guselkumab Effects on Uncontrolled Psoriatic Arthritis in Participants With Moderate, Low Body Surface Area, High-Impact Site Psoriasis Through Week 48
Joseph F. Merola, Richard G. Langley, Maryam Shayesteh-Alam, Andrea Nguyen, Theodore Alkousakis, Sarah Ofori, Elizabeth Adamson, Jenny Jeyarajah, Gabriela Cobos, Alice B. Gottlieb
SPECTREM: High-Impact Site Skin Clearance and Itch Improvement Through Week 48 With Guselkumab in Participants With Low Body Surface Area, Moderate Psoriasis
Bruce Strober, Kim A. Papp, April W. Armstrong, Alice B. Gottlieb, James G. Krueger, Theodore Alkousakis, Katelyn Rowland, Daphne Chan, Jenny Jeyarajah, Laura Park-Wyllie, Robert Bissonnette
Treatment of Plaque Psoriasis Involving High-Impact Sites With Icotrokinra, a Targeted Oral Peptide: Pooled Analyses of Four Phase 3 Placebo-Controlled Trials
Jennifer Soung, April W. Armstrong, Ronald B. Vender, Josep Riera-Monroig, Michael Sebastian, Ofelia Reyes-Servin, Bassey Effiom Edem, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Linda Stein Gold
Unmet Needs and Disease Burden: Perspectives From Adults With Psoriasis and Clinicians Treating Psoriasis in Germany and the US
Matthias Augustin, Linda Stein Gold, Eva Vilarrasa, Jennifer Soung, Nina Trenkler, Melina Taylor, Ashley Duenas, Ya-Wen Yang, Jensen Lewis, Gale Harding, Torben Kasparek, Guo Li, Mona Shahriari
VISIBLE: Guselkumab Impact on Psoriatic Arthritis Through Week 100 in Participants With Moderate-to-Severe Psoriasis and Uncontrolled Psoriatic Arthritis Across All Skin Tones
Joseph F. Merola, Richard G. Langley, Maryam Shayesteh-Alam, Andrea Nguyen, Theodore Alkousakis, Sarah Ofori, Elizabeth Adamson, Tony Ma, Joe K. Tung, Alice B. Gottlieb
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.
Connect with us
Connect with us
Would you like to clear and leave your conversation? Message history will be lost.